Less than one month after receiving approval for generic equivalents of Novo Nordisk’s Ozempic® in Canada, Apotex and Dr Reddy’s have launched their generic semaglutide products on the Canadian market.
Apotex announced its launch of Apo-Semaglutide Injection™ on 14 May 2026, stating that initial inventory is available and is shipping to wholesalers and that the product will be on pharmacy shelves in Canada “within the coming weeks”. Dr Reddy’s Canadian launch announcement quickly followed on 16 May 2026, with the company stating that the launch of its “Semaglutide Injection” demonstrates “Dr Reddy’s readiness to ensure patient access following approval”. Both products are indicated for adults with type 2 diabetes and are supplied in pre-filled pens.
Dr Reddy’s was one of the first companies to receive approval for, and launch, generic semaglutide in India (under the name Obeda™). Meanwhile, Apotex received the first US FDA Tentative Approval for its generic semaglutide ANDA, giving it an opportunity to be one of the first to launch generic Ozempic® in the US following expiry of Novo Nordisk’s exclusivity/patents.
It has previously been reported that Health Canada is reviewing numerous submissions for generic semaglutide, including applications by Teva, Aspen Pharmacare, Taro Pharmaceuticals and Sandoz (which is planning a 2026 generic semaglutide launch in Canada). Further generic semaglutide approvals and launches are therefore expected in Canada in the coming months.